Sage Therapeutics (SAGE) Posts Q2 Loss of $4.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Starts Sage Therapeutics (SAGE) at Outperform
August 12, 2014 7:46 AM EDTLeerink Swann initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $46.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Sage Therapeutics (SAGE) at Buy
August 12, 2014 7:45 AM EDT(Updated - August 12, 2014 11:16 AM EDT)
Canaccord Genuity initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $40.00.
Analyst John Newman said, "We are initiating coverage on SAGE Therapeutics... More
JPMorgan Starts Sage Therapeutics (SAGE) at Overweight
August 12, 2014 7:45 AM EDTJPMorgan initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Overweight rating and a price target of $42.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
... MoreGoldman Sachs Starts Sage Therapeutics (SAGE) at Neutral
August 12, 2014 7:44 AM EDTGoldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Neutral rating and a price target of $38.00.
Analyst Navdeep Singh said, "Sage is a small-cap biotech focused on developing drugs for central nervous... More
